Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation
Aloïs Gratwohl, Jane F. Apperley(Hammersmith Hospital), Eoin McGrath(European Molecular Biology Laboratory), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Per Ljungman(Karolinska University Hospital), Anja van Biezen(European Society for Blood and Marrow Transplantation), Helen Baldomero(University Hospital of Basel), R. Brand(Leiden University Medical Center), Christian Chabannon(Inserm)
Cited by 100
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k